Log In
BCIQ
Print this Print this
 

IMA950

  Manage Alerts
Collapse Summary General Information
Company immatics biotechnologies GmbH
DescriptionVaccine containing 11 different human leukocyte antigen (HLA)-restricted tumor-associated peptides (TUMAPs)
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationBrain cancer
Indication DetailsTreat glioblastoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today